[{"id":"61d56240-acd7-4036-be44-40ad727ab77a","acronym":"A051701","url":"https://clinicaltrials.gov/study/NCT03984448","created_at":"2021-01-18T19:35:47.901Z","updated_at":"2025-02-25T15:11:12.787Z","phase":"Phase 2/3","brief_title":"Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas","source_id_and_acronym":"NCT03984448 - A051701","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MYC • BCL2 • BCL6","pipe":" | ","alterations":" BCL2 expression • MYC expression • MYC translocation • MYC negative • BCL2 translocation","tags":["MYC • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression • MYC expression • MYC translocation • MYC negative • BCL2 translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 363","initiation":"Initiation: 10/22/2019","start_date":" 10/22/2019","primary_txt":" Primary completion: 04/01/2028","primary_completion_date":" 04/01/2028","study_txt":" Completion: 04/01/2028","study_completion_date":" 04/01/2028","last_update_posted":"2025-02-13"},{"id":"c84b4894-7b72-40e5-b7d9-73619eecd885","acronym":"22P.205","url":"https://clinicaltrials.gov/study/NCT05564650","created_at":"2022-10-03T15:56:48.447Z","updated_at":"2025-02-25T15:35:52.261Z","phase":"Phase 1/2","brief_title":"Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome","source_id_and_acronym":"NCT05564650 - 22P.205","lead_sponsor":"Thomas Jefferson University","biomarkers":" BCL2","pipe":" | ","alterations":" BCL2 expression","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • decitabine • navitoclax (ABT 263)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 01/12/2023","start_date":" 01/12/2023","primary_txt":" Primary completion: 04/10/2026","primary_completion_date":" 04/10/2026","study_txt":" Completion: 04/10/2026","study_completion_date":" 04/10/2026","last_update_posted":"2025-02-11"},{"id":"fbd6bc02-c103-44b1-a7a6-46bf853b12db","acronym":"","url":"https://clinicaltrials.gov/study/NCT03808610","created_at":"2021-01-18T18:49:14.679Z","updated_at":"2025-02-25T15:34:18.507Z","phase":"Phase 1/2","brief_title":"Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT03808610","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BCL2","pipe":" | ","alterations":" BCL2 expression","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Rituxan (rituximab) • cytarabine • cyclophosphamide • methotrexate • vincristine • Oncaspar liquid (pegaspargase) • Truxima (rituximab-abbs) • nelarabine • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • Novex (rituximab biosimilar) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 04/03/2019","start_date":" 04/03/2019","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-10"},{"id":"e4540d59-4ee0-4d85-b168-8b3f90bd2231","acronym":"","url":"https://clinicaltrials.gov/study/NCT06317662","created_at":"2024-03-19T13:40:49.211Z","updated_at":"2025-02-25T17:39:56.997Z","phase":"Phase 2","brief_title":"Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia","source_id_and_acronym":"NCT06317662","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MCL1 • KMT2A • BCL2L1","pipe":" | ","alterations":" BCL2 expression","tags":["MCL1 • KMT2A • BCL2L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • Asparlas (calaspargase pegol-mknl) • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • prednisolone"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 171","initiation":"Initiation: 04/26/2025","start_date":" 04/26/2025","primary_txt":" Primary completion: 12/31/2028","primary_completion_date":" 12/31/2028","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2025-01-29"},{"id":"b2736ad5-0c4c-46cb-878a-ca7131168d3c","acronym":"","url":"https://clinicaltrials.gov/study/NCT00001337","created_at":"2021-01-17T22:44:38.987Z","updated_at":"2024-07-02T16:34:25.642Z","phase":"Phase 2","brief_title":"Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT00001337","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2","pipe":" | ","alterations":" BCL2 expression","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab)"],"overall_status":"Completed","enrollment":" Enrollment 348","initiation":"Initiation: 05/08/1993","start_date":" 05/08/1993","primary_txt":" Primary completion: 05/24/2024","primary_completion_date":" 05/24/2024","study_txt":" Completion: 05/24/2024","study_completion_date":" 05/24/2024","last_update_posted":"2024-06-17"},{"id":"9d08cc44-2ff2-4ddf-8a4a-45f9d74b95ce","acronym":"","url":"https://clinicaltrials.gov/study/NCT03319901","created_at":"2021-01-18T16:23:44.923Z","updated_at":"2024-07-02T16:35:00.283Z","phase":"Phase 1/2","brief_title":"Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL","source_id_and_acronym":"NCT03319901","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" BCL2","pipe":" | ","alterations":" BCL2 expression • MCL1 expression","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression • MCL1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax)"],"overall_status":"Recruiting","enrollment":" Enrollment 82","initiation":"Initiation: 10/30/2017","start_date":" 10/30/2017","primary_txt":" Primary completion: 04/30/2026","primary_completion_date":" 04/30/2026","study_txt":" Completion: 04/30/2027","study_completion_date":" 04/30/2027","last_update_posted":"2024-05-29"},{"id":"3a37bc3c-8cd8-4398-97d2-6d24383dcff4","acronym":"","url":"https://clinicaltrials.gov/study/NCT04188405","created_at":"2021-01-18T20:24:56.671Z","updated_at":"2024-07-02T16:35:06.506Z","phase":"Phase 2","brief_title":"Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia","source_id_and_acronym":"NCT04188405","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ABL1 • BCR • BCL2","pipe":" | ","alterations":" BCL2 expression","tags":["ABL1 • BCR • BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Iclusig (ponatinib) • azacitidine • decitabine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/17/2020","start_date":" 05/17/2020","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2024-05-02"},{"id":"f374dc4d-c613-437c-8a29-943b1442e3ca","acronym":"","url":"https://clinicaltrials.gov/study/NCT01303341","created_at":"2021-01-18T05:18:01.764Z","updated_at":"2024-07-02T16:35:13.428Z","phase":"Phase 1","brief_title":"Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma","source_id_and_acronym":"NCT01303341","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2","pipe":" | ","alterations":" BCL2 expression • MCL1 expression","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression • MCL1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • riluzole"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 02/18/2011","start_date":" 02/18/2011","primary_txt":" Primary completion: 05/01/2012","primary_completion_date":" 05/01/2012","study_txt":" Completion: 09/09/2024","study_completion_date":" 09/09/2024","last_update_posted":"2024-03-21"},{"id":"92f3f7c6-e282-4c02-a649-a3d88aca09fb","acronym":"","url":"https://clinicaltrials.gov/study/NCT04953780","created_at":"2024-03-18T13:21:29.779Z","updated_at":"2024-07-02T16:35:14.325Z","phase":"Phase 1","brief_title":"2157GCCC:Phase 1 of Calaspargase Pegol-mknl w/ Cytarabine and Idarubicin in Newly Dx AML","source_id_and_acronym":"NCT04953780","lead_sponsor":"University of Maryland, Baltimore","biomarkers":" MCL1 • BCL2L1","pipe":" | ","alterations":" BCL2 expression","tags":["MCL1 • BCL2L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • idarubicin hydrochloride • Asparlas (calaspargase pegol-mknl)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 09/27/2021","start_date":" 09/27/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-03-18"},{"id":"da510deb-65e1-4eff-9b8a-b593ca5424f3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05147467","created_at":"2024-01-23T19:20:01.388Z","updated_at":"2024-07-02T16:35:22.580Z","phase":"Phase 2","brief_title":"Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL","source_id_and_acronym":"NCT05147467","lead_sponsor":"Ascentage Pharma Group Inc.","biomarkers":" BCL2","pipe":" | ","alterations":" BCL2 expression","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lisaftoclax (APG-2575)"],"overall_status":"Recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 12/28/2021","start_date":" 12/28/2021","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-01-23"},{"id":"300dc214-2f53-46f4-88db-099cbeecb27f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05755087","created_at":"2023-03-06T15:01:37.165Z","updated_at":"2024-07-02T16:35:24.905Z","phase":"Phase 1","brief_title":"Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma","source_id_and_acronym":"NCT05755087","lead_sponsor":"Lapo Alinari","biomarkers":" MYC • BCL2 • BCL6","pipe":" | ","alterations":" BCL2 expression • MYC expression • MYC translocation • MYC translocation + BCL2 translocation • BCL2 translocation","tags":["MYC • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression • MYC expression • MYC translocation • MYC translocation + BCL2 translocation • BCL2 translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tegavivint (BC2059)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 03/06/2023","start_date":" 03/06/2023","primary_txt":" Primary completion: 03/05/2027","primary_completion_date":" 03/05/2027","study_txt":" Completion: 03/05/2027","study_completion_date":" 03/05/2027","last_update_posted":"2023-12-29"},{"id":"63d174f5-1045-41f8-a030-f399abb4d1dd","acronym":"NCI-2016-00073","url":"https://clinicaltrials.gov/study/NCT02697344","created_at":"2021-01-18T13:10:03.223Z","updated_at":"2024-07-02T16:35:25.022Z","phase":"Phase 1","brief_title":"Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple Myeloma","source_id_and_acronym":"NCT02697344 - NCI-2016-00073","lead_sponsor":"Mayo Clinic","biomarkers":" BCL2 • CRBN • MAPK1","pipe":" | ","alterations":" BCL2 expression • CRBN expression","tags":["BCL2 • CRBN • MAPK1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression • CRBN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • dexamethasone • R-(-)-gossypol (AT 101)"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 04/14/2016","start_date":" 04/14/2016","primary_txt":" Primary completion: 10/26/2018","primary_completion_date":" 10/26/2018","study_txt":" Completion: 12/20/2023","study_completion_date":" 12/20/2023","last_update_posted":"2023-12-28"},{"id":"f819fdca-d47b-44d9-bff9-cba461ae961d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04214626","created_at":"2021-01-18T20:31:21.284Z","updated_at":"2024-07-02T16:35:27.097Z","phase":"Phase 2","brief_title":"R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma","source_id_and_acronym":"NCT04214626","lead_sponsor":"Henan Cancer Hospital","biomarkers":" MYC • BCL2","pipe":" | ","alterations":" BCL2 expression • MYC expression • TP53 expression","tags":["MYC • BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression • MYC expression • TP53 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • lenalidomide • cyclophosphamide • epirubicin • vincristine • prednisone • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/02/2020","start_date":" 01/02/2020","primary_txt":" Primary completion: 11/29/2023","primary_completion_date":" 11/29/2023","study_txt":" Completion: 01/02/2025","study_completion_date":" 01/02/2025","last_update_posted":"2023-12-05"},{"id":"6a4eb48f-d80a-4473-8435-28c248997a37","acronym":"","url":"https://clinicaltrials.gov/study/NCT05222438","created_at":"2022-02-05T18:29:17.280Z","updated_at":"2024-07-02T16:35:30.883Z","phase":"Phase 2","brief_title":"Trial of Loncastuximab Tesirine in High Risk Diffuse Large B-cell Lymphoma Post Transplant","source_id_and_acronym":"NCT05222438","lead_sponsor":"Barbara Ann Karmanos Cancer Institute","biomarkers":" MYC • BCL2 • CD19 • BCL6","pipe":" | ","alterations":" CD19 positive • BCL2 expression • CD19 expression • BCL6 rearrangement • BCL2 rearrangement","tags":["MYC • BCL2 • CD19 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • BCL2 expression • CD19 expression • BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zynlonta (loncastuximab tesirine-lpyl)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 04/08/2022","start_date":" 04/08/2022","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-11-01"},{"id":"26065744-c262-4f87-91b1-e6294c2cfbc7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04323956","created_at":"2021-01-18T20:56:54.236Z","updated_at":"2024-07-02T16:35:31.265Z","phase":"Phase 1","brief_title":"Parsaclisib With or Without Polatuzumab Vedotin Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma","source_id_and_acronym":"NCT04323956","lead_sponsor":"Mayo Clinic","biomarkers":" MYC • BCL2 • CD20 • BCL6","pipe":" | ","alterations":" BCL2 expression • MYC expression • CD20 expression • MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement","tags":["MYC • BCL2 • CD20 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression • MYC expression • CD20 expression • MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Truxima (rituximab-abbs) • parsaclisib (INCB50465) • Polivy (polatuzumab vedotin-piiq) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • Neulasta (pegfilgrastim) • Fulphila (pegfilgrastim-jmdb) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Neupogen (filgrastim) • Novex (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 06/15/2020","start_date":" 06/15/2020","primary_txt":" Primary completion: 05/15/2026","primary_completion_date":" 05/15/2026","study_txt":" Completion: 05/15/2027","study_completion_date":" 05/15/2027","last_update_posted":"2023-10-30"},{"id":"605a0b17-821b-4ac1-bac6-146b7cba1964","acronym":"BELLINI","url":"https://clinicaltrials.gov/study/NCT02755597","created_at":"2021-01-17T17:25:35.201Z","updated_at":"2024-07-02T16:35:39.378Z","phase":"Phase 3","brief_title":"A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy","source_id_and_acronym":"NCT02755597 - BELLINI","lead_sponsor":"AbbVie","biomarkers":" BCL2","pipe":" | ","alterations":" BCL2 expression","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • bortezomib • dexamethasone"],"overall_status":"Completed","enrollment":" Enrollment 291","initiation":"Initiation: 07/11/2016","start_date":" 07/11/2016","primary_txt":" Primary completion: 03/15/2021","primary_completion_date":" 03/15/2021","study_txt":" Completion: 08/15/2022","study_completion_date":" 08/15/2022","last_update_posted":"2023-08-22"},{"id":"08c24232-e226-466d-ad87-b0c0cb2e04f3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05951426","created_at":"2023-07-20T14:08:38.750Z","updated_at":"2024-07-02T16:35:42.537Z","phase":"","brief_title":"Expression Analysis of the COPB 2 and Bcl-2 in Early Stages of Endometrial Carcinoma","source_id_and_acronym":"NCT05951426","lead_sponsor":"Clinical Center Kragujevac","biomarkers":" BCL2","pipe":" | ","alterations":" BCL2 expression","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 04/17/2019","start_date":" 04/17/2019","primary_txt":" Primary completion: 12/21/2021","primary_completion_date":" 12/21/2021","study_txt":" Completion: 10/01/2022","study_completion_date":" 10/01/2022","last_update_posted":"2023-07-19"},{"id":"790ce6b7-44f9-4447-9759-09e1b262a8bf","acronym":"ECOG-ACRIN EA9152","url":"https://clinicaltrials.gov/study/NCT03504644","created_at":"2021-01-18T17:15:14.614Z","updated_at":"2024-07-02T16:35:44.927Z","phase":"Phase 1/2","brief_title":"Venetoclax and Vincristine Liposomal in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT03504644 - ECOG-ACRIN EA9152","lead_sponsor":"ECOG-ACRIN Cancer Research Group","biomarkers":" BCL2","pipe":" | ","alterations":" BCL2 expression","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Marqibo (vincristine liposomal)"],"overall_status":"Recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 08/13/2018","start_date":" 08/13/2018","primary_txt":" Primary completion: 12/31/2028","primary_completion_date":" 12/31/2028","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2023-06-23"},{"id":"846c7816-a265-4367-9445-7a5279012747","acronym":"","url":"https://clinicaltrials.gov/study/NCT03236857","created_at":"2021-01-18T15:59:38.618Z","updated_at":"2024-07-02T16:35:47.459Z","phase":"Phase 1","brief_title":"A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies","source_id_and_acronym":"NCT03236857","lead_sponsor":"AbbVie","biomarkers":" BCL2 • TCF3","pipe":" | ","alterations":" BCL2 expression","tags":["BCL2 • TCF3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • azacitidine • cyclophosphamide"],"overall_status":"Completed","enrollment":" Enrollment 143","initiation":"Initiation: 11/08/2017","start_date":" 11/08/2017","primary_txt":" Primary completion: 04/19/2023","primary_completion_date":" 04/19/2023","study_txt":" Completion: 04/19/2023","study_completion_date":" 04/19/2023","last_update_posted":"2023-05-22"},{"id":"0a498da3-5052-4cfe-b07c-4435fee18fe1","acronym":"","url":"https://clinicaltrials.gov/study/NCT04668365","created_at":"2021-01-19T20:44:06.435Z","updated_at":"2024-07-02T16:35:47.692Z","phase":"Phase 2","brief_title":"Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma","source_id_and_acronym":"NCT04668365","lead_sponsor":"Henan Cancer Hospital","biomarkers":" MYC • BCL2 • CD79B • CD79A","pipe":" | ","alterations":" BCL2 expression • MYC expression","tags":["MYC • BCL2 • CD79B • CD79A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression • MYC expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Rituxan (rituximab) • cytarabine • cyclophosphamide • oxaliplatin • Brukinsa (zanubrutinib) • epirubicin • vincristine • prednisone • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 59","initiation":"Initiation: 12/25/2020","start_date":" 12/25/2020","primary_txt":" Primary completion: 12/25/2023","primary_completion_date":" 12/25/2023","study_txt":" Completion: 12/25/2025","study_completion_date":" 12/25/2025","last_update_posted":"2023-05-18"},{"id":"a1df6c8b-2a63-439b-b62a-42b53c75ace9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05527912","created_at":"2022-09-06T17:03:03.863Z","updated_at":"2024-07-02T16:35:49.736Z","phase":"Phase 2","brief_title":"A Phase II Study of Rituximab, Chidamide, Zanubrutinib-induced and CHOP Therapy","source_id_and_acronym":"NCT05527912","lead_sponsor":"Sun Yat-sen University","biomarkers":" MYC • BCL2","pipe":" | ","alterations":" BCL2 expression • MYC expression","tags":["MYC • BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression • MYC expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Brukinsa (zanubrutinib) • Epidaza (chidamide)"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 02/24/2023","start_date":" 02/24/2023","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-04-25"},{"id":"2bb7d6c9-0473-46c7-9460-ae9487c6e000","acronym":"","url":"https://clinicaltrials.gov/study/NCT04679480","created_at":"2021-01-19T20:46:22.519Z","updated_at":"2024-07-02T16:36:00.949Z","phase":"Phase 2","brief_title":"Anti-PD1-antibody and Pulsed HHI for Advanced BCC","source_id_and_acronym":"NCT04679480","lead_sponsor":"Reinhard Dummer","biomarkers":" CD8 • PD-1 • CD4 • CD200 • FOXP3","pipe":" | ","alterations":" PD-L1 expression • PD-1 expression • BCL2 expression • CD20 expression • CD200 expression","tags":["CD8 • PD-1 • CD4 • CD200 • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-1 expression • BCL2 expression • CD20 expression • CD200 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Libtayo (cemiplimab-rwlc) • Odomzo (sonidegib)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 02/18/2021","start_date":" 02/18/2021","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2022-11-04"},{"id":"bcba688d-ccf2-45b4-927a-b48dc238e7e9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05596097","created_at":"2022-10-27T15:58:27.582Z","updated_at":"2024-07-02T16:36:01.746Z","phase":"Phase 2","brief_title":"Zanubrutinib in Maintenance Therapy of DLBCL Patients With Initial Remission","source_id_and_acronym":"NCT05596097","lead_sponsor":"LanZhou University","biomarkers":" TP53 • MYC • BCL2 • MYD88 • BCL6 • CD79B • CD79A","pipe":" | ","alterations":" BCL2 expression • MYC expression","tags":["TP53 • MYC • BCL2 • MYD88 • BCL6 • CD79B • CD79A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression • MYC expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Brukinsa (zanubrutinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 10/30/2022","start_date":" 10/30/2022","primary_txt":" Primary completion: 10/20/2024","primary_completion_date":" 10/20/2024","study_txt":" Completion: 07/30/2026","study_completion_date":" 07/30/2026","last_update_posted":"2022-10-27"},{"id":"e92471d9-fc4e-4170-a0ba-e8d100dcff1e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05456022","created_at":"2022-07-13T12:56:27.026Z","updated_at":"2024-07-02T16:36:07.358Z","phase":"Phase 2","brief_title":"Therapeutic Efficacy of Quercetin Versus Its Encapsulated Nanoparticle on Tongue Squamous Cell Carcinoma Cell Line","source_id_and_acronym":"NCT05456022","lead_sponsor":"Cairo University","biomarkers":" BCL2 • BAX • GAPDH • ANXA5","pipe":" | ","alterations":" BCL2 expression • BAX expression","tags":["BCL2 • BAX • GAPDH • ANXA5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression • BAX expression"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 1000000","initiation":"Initiation: 07/01/2022","start_date":" 07/01/2022","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2022-07-13"}]